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Abstract 
Vibrio cholerae converts glucose into either acid or the neutral end product acetoin and its survival in carbohydrate 
enriched media is linked to the nature of the byproducts produced. It has been demonstrated in this study that 
Escherichia coli strain isolated from the gut of healthy human volunteers and the commonly used probiotic E. coli 
Nissle strain that metabolize glucose to acidic byproducts drastically reduce the survival of V. cholerae strains irre-
spective of their glucose sensitivity and acetoin production status. Accordingly, E. coli glucose transport mutants 
that produce lower amounts of acidic metabolites had little effect on the survival of V. cholerae in cocultures. Thus, 
cross feeding of byproducts of glucose metabolism by heterologous bacteria modulates the survival of V. cholerae in 
glucose rich medium suggesting that composition of the gut microbiota could influence the outcome of V. cholerae 
infection especially when glucose based ORS is administered.
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Background
Successful infection by bacterial pathogens depends pri-
marily upon a complex interplay between bacterial viru-
lence factors and host responses and defense systems. 
Recently however, it is becoming apparent that presence 
of other microorganisms might profoundly influence the 
outcome of bacterial infections including that of Vibrio 
cholerae [1]. In this study we demonstrate that presence 
of heterologous organisms, with ability to produce acidic 
byproducts of glucose metabolism might modulate the 
survival of V. cholerae under glucose rich conditions.
All recorded cholera pandemics have been caused by 
strains of the O1 serogroup of V. cholerae that can be 
classified into two major biotypes, classical and El Tor. 
Although the classical and El Tor biotypes are closely 
related, several biochemical and genetic differences 
have been reported between the two biotypes including 
a unique difference in carbohydrate metabolism. In the 
presence of exogenous sugars the classical biotype strains 
(e.g. O395) produced organic acids resulting in a sharp 
decrease in media pH and drastic loss of viability. El Tor 
strains (e.g. N16961) have evolved to metabolize sugars 
to produce acetoin, a neutral fermentation end-prod-
uct that did not inhibit bacterial growth [2]. It has been 
suggested that the ability to metabolize sugars without 
production of growth inhibitory acidic products might 
account for the evolutionary fitness of the V. cholerae El 
Tor biotype by virtue of which it displaced the classical 
biotype as a cause of epidemic cholera [2].
Here, we postulate that cross feeding of byproducts of 
glucose metabolism by heterologous bacteria might mod-
ulate the survival of V. cholerae in glucose rich growth 
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medium. As proof of concept, V. cholerae classical and 
El Tor biotype strains were co-cultured in the presence 
of glucose with E.coli strains that produce acidic byprod-
ucts of glucose metabolism, and the effect of co-culturing 
on V. cholerae survival was determined. We observed a 
drastic loss of viability of V. cholerae strains irrespective 
of their acetoin production status in the co-culture with 
E. coli strains under carbohydrate rich condition. On the 
other hand, E. coli glucose transport mutants that pro-
duce lower amounts of acidic metabolites had little effect 
on the survival of V. cholerae in co-cultures.
Methods
Strains
All bacterial strains used for this study have been 
described in Additional file 1: Table S1. Bacterial cultures 
grown to the logarithmic phase in Luria broth (LB) were 
stored in glycerol (10% v/v) at −80  °C. When required, 
streptomycin was used at a concentration of 100 μg/ml.
Coculture studies
V. cholerae El Tor strain N16961 (SmR) or classical strain 
O395 (SmR) and E. coli strains mentioned in Table S1, 
were grown in LB medium up to mid-logarithmic phase. 
Cocultures (1:1) were set up in LB or LB containing 1% 
glucose (LBG). Monocultures were set up in LB and LBG 
in a similar manner as a control. At regular intervals ali-
quots of the cultures were removed and the number of V. 
cholerae cells was enumerated by serial dilution and plat-
ing on Luria agar containing streptomycin (100  μg/ml). 
At all time points, pH in the culture supernatants was 
measured. Statistical significance of the data has been 
calculated and expressed as ±SD in all experiments.
Spotting assays
Survival of V. cholerae N16961 strain in cell free condi-
tioned medium was assayed by spotting on LA plates 
containing streptomycin (100  μg/ml). Cell free con-
ditioned medium was prepared from 12  h cultures of 
N16961 and E. coli strains grown in LB or LBG at 37 °C 
with aeration. Mid-logarithmic phase V. cholerae N16961 
was resuspended in the conditioned medium and cul-
tures were allowed to grow for 12 h at 37 °C with aeration. 
Survival was assayed by spotting dilutions (10−3–10−6) 
on LB agar plates containing streptomycin to select V. 
cholerae N16961 (SmR).
Results and discussion
To ascertain how the survival of V. cholerae is influenced 
by heterologous bacteria in glucose enriched medium, 
V. cholerae classical and El Tor biotypes strains were co-
cultured with wild type E. coli strains (Additional file 1: 
Table S1) in the presence or absence of glucose. The E. 
coli strains produce largely acidic metabolites upon glu-
cose fermentation [3–5]; it is therefore conceivable that 
the survival of V. cholerae may be affected in the co-cul-
ture with E. coli in LBG.
As reported earlier, V. cholerae classical biotype strain 
O395 exhibited severe growth defect in Luria broth 
medium supplemented with 1% glucose (LBG) since this 
biotype produces acidic byproducts of glucose metabo-
lism. On the other hand, V. cholerae El Tor biotype strain 
N16961 that metabolizes glucose to acetoin, could grow 
normally in LBG [2]. However, when the strains were 
grown in co-cultures with E. coli 40 or E. coli Nissle, 
a drastic decline in cell count of both the V. cholerae 
strains was observed concomitant with acidification of 
the growth media presumably due to acidic glucose fer-
mentation metabolites produced by E. coli (Fig. 1). Inter-
estingly, it was noted that although N16961 is capable of 
producing acetoin in LBG medium, it failed to overcome 
the lethal effect of strong acidification caused by the E. 
coli strains. These results suggest that E. coli strains by 
virtue of their ability to metabolize glucose to acidic 
byproducts and cause acidification of the growth medium 
in LBG, affect survival of V. cholerae strains irrespective 
of the acetoin producing capability of the latter, when 
the E. coli and V. cholerae strains are grown together. To 
examine if acidification of the medium by acidic byprod-
ucts of glucose metabolism during growth of E. coli cul-
tures in LBG was primarily responsible for the killing 
of V. cholerae strains in the co-cultures, the V. cholerae 
strains were next co-cultured with the E. coli MG1655 
glucose transport mutants (Additional file 1: Table S1). In 
these co-cultures much lower acidification of the growth 
medium was observed and survival of the V. cholerae 
strains was much higher than that in co-cultures with 
the wild type E. coli strains (Fig.  2) strongly suggesting 
that glucose uptake and metabolism produced acidic 
byproducts and the resulting acidification of the media 
in wild type E. coli cultures resulted in severe decline in 
cell count of V. cholerae strains in LBG. Suspension of V. 
cholerae strain N16961 in conditioned medium prepared 
from 12 h cultures of E. coli resulted in loss of cell count 
indicating that cell–cell contact was not necessary for the 
decline in cell count of V. cholerae in the presence of the 
E. coli strains (Additional file 2: Fig. S1). 
Based on its interaction with host, E. coli strains can 
be categorized broadly into non pathogenic commensal 
and pathogenic groups. The pathogenic groups can be 
further divided into intestinal pathogenic and extra intes-
tinal pathogenic strains [6, 7]. Interestingly, the commen-
sal and probiotic E. coli EcN strain has been exploited 
clinically to ameliorate the burden of ulcerative coli-
tis and Crohn’s disease [8–10]. Other than clinical use, 
EcN as well as other non pathogenic E. coli strains have 
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been evaluated for their potential as delivery vehicles 
[11], in reducing intestinal colonization of Salmonella 
typhimurium [12] and in cancer therapy [13]. Though 
non pathogenic commensal and probiotic E. coli strains 
have tremendous potential for therapeutic use, it must be 
borne in mind that efficacy of such strains as probiotics 
is strongly dependent on the composition of intestinal 
microbiota and immune status of host [14].
Conclusion
In essence, this study suggests that preponderance of 
bacterial strains that metabolize glucose to acidic com-
pounds in the gut might hinder V. cholerae survival. The 
result is particularly important as glucose based oral 
rehydration therapy is currently highly recommended 
during cholera infections. Thus, selected E. coli strains 
isolated from healthy human gut and commonly used 
Fig. 1 Cocultures of V. cholerae with E. coli strains.CFU of V. cholerae El Tor strain N16961 (SmR) was enumerated in individual cultures (a) or in cocul-
tures (1:1) with E. coli 40 (Ec40) or E. coli Nissle (EcN) (b) at different time points. At all time points, pH of the culture supernatants was measured (c). 
CFU of V. cholerae classical strain O395 (SmR) in mono- and co-cultures was similarly assayed and pH of the culture supernatants was measured (d)
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probiotic E. coli Nissle that metabolize glucose to acidic 
byproducts could be used as probiotics together with 
ORT for the control of cholera.
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Fig. 2 Cocultures of V. cholerae with E. coli WT and glucose transport mutants. V. cholerae N16961 (SmR) was grown together with E. coli MG1655 or 
glucose transport mutants (1:1 ratio) in LB medium containing glucose (1%). At regular intervals CFU of V. cholerae cells was determined (a) and pH 
of the culture supernatants was measured (b)
